Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1.
Details
Serval ID
serval:BIB_B0260947430D
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1.
Journal
Anticancer Research
ISSN
1791-7530 (Electronic)
ISSN-L
0250-7005
Publication state
Published
Issued date
2011
Peer-reviewed
Oui
Volume
31
Number
10
Pages
3115-3124
Language
english
Notes
Publication types: Journal Article
Abstract
BACKGROUND: High-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) is used for the treatment of hemato-oncologic malignancies. In this study, we measured the effect of HDC/ASCT on plasma concentrations of antiangiogenic soluble vascular endothelial growth factor receptor 1 (sVEGFR1) and of leukapheresis products (LP) and patient serum on chick chorioallantoic (CAM) angiogenesis.
MATERIALS AND METHODS: VEGFR1- and CD34-expressing cells of leukapheresis products were analyzed by flow cytometry. Alternatively spliced isoforms of VEGFR1 mRNA were quantified using reverse transcription PCR.
RESULTS: Plasma concentrations of sVEGFR1 decreased after HDC, but significantly increased after ASCT. In the CAM assay, sera of patients elicited a proangiogenic effect before and after HDC, but a strong antiangiogenic response after ASCT, comparable to that of bevacizumab at therapeutic concentrations. LP contains high concentrations of sVEGFR1, and high density of VEGFR1(+) neutrophilic granulocytes, in which mRNA expression is shifted toward the soluble VEGFR1 isoform.
CONCLUSION: Neutrophil-derived antiangiogenic sVEGFR1 within the LP may contribute to the therapeutic efficacy of ASCT.
MATERIALS AND METHODS: VEGFR1- and CD34-expressing cells of leukapheresis products were analyzed by flow cytometry. Alternatively spliced isoforms of VEGFR1 mRNA were quantified using reverse transcription PCR.
RESULTS: Plasma concentrations of sVEGFR1 decreased after HDC, but significantly increased after ASCT. In the CAM assay, sera of patients elicited a proangiogenic effect before and after HDC, but a strong antiangiogenic response after ASCT, comparable to that of bevacizumab at therapeutic concentrations. LP contains high concentrations of sVEGFR1, and high density of VEGFR1(+) neutrophilic granulocytes, in which mRNA expression is shifted toward the soluble VEGFR1 isoform.
CONCLUSION: Neutrophil-derived antiangiogenic sVEGFR1 within the LP may contribute to the therapeutic efficacy of ASCT.
Keywords
Angiogenesis Inhibitors/pharmacology, Angiogenesis Inhibitors/therapeutic use, Animals, Antigens, CD34/metabolism, Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Chickens, Chorioallantoic Membrane/drug effects, Chorioallantoic Membrane/metabolism, Enzyme-Linked Immunosorbent Assay, Gene Expression Regulation, Neoplastic/drug effects, Humans, Leukapheresis, Neovascularization, Pathologic/drug therapy, Neutrophils/drug effects, Neutrophils/metabolism, RNA, Messenger/genetics, RNA, Messenger/metabolism, Solubility/drug effects, Stem Cell Transplantation, Transplantation, Autologous, Vascular Endothelial Growth Factor Receptor-1/blood, Vascular Endothelial Growth Factor Receptor-1/genetics
Pubmed
Web of science
Create date
09/01/2013 17:49
Last modification date
20/08/2019 16:19
Usage data
